Sept 1 (Reuters) – GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Sherry Jacob-Phillips)
Comments